Viking Therapeutics Q4 2021 Earnings Report
Key Takeaways
Viking Therapeutics reported a net loss of $12.4 million, or $0.16 per share, for the fourth quarter ended December 31, 2021. The company's research and development expenses were $9.8 million, and general and administrative expenses were $2.7 million. The company ended the quarter with $202.1 million in cash, cash equivalents and short-term investments.
Enrollment continued in the Phase 2b VOYAGE trial evaluating VK2809 for the treatment of NASH and fibrosis.
A Phase 1b trial evaluating VK0214 in X-ALD patients was placed on hold pending completion of a preclinical study.
A Phase 1 trial of the novel dual incretin receptor agonist VK2735 is underway.
The company ended the fourth quarter with $202.1 million in cash, cash equivalents and short-term investments.